Latest receivables for ASND: $200M.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
As of the most recent data (March 2026), ASND shows a receivables of $200M. That compares with $77M in the prior-year period — up 156.2% year over year. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, ASND's receivables is now $200M (was $77M) — a 156.2% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Ascendis Pharma A/S is outperforming or lagging.
Tracking ASND's receivables over time shows whether Ascendis Pharma A/S is scaling, shrinking, or reshaping that part of the business. The current reading is $200M That compares with $77M in the prior-year period — up 156.2% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this receivables page, Stockcircle has Ascendis Pharma A/S's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $200M) with ownership activity and broader fundamentals.
Ascendis Pharma A/S's receivables is $200M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.